CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn is a biotech that has been effective conscientiously but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, along with Vyrologix.
In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.
CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is an open question.
While CYDY happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.
I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. My 1st CytoDyn post, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set away the following prediction:
Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire interview which I came away with a bad viewpoint of the business.
Irony of irony, the bad viewpoint of mine of the company has grown steadily, although the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.
What manner of stock is this that gives a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.
CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back during 2012, announced as follows:
CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment and avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this expertise and also connected intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) as well as the very first brand new drug application endorsement ($5 million), and also royalty payments of five % of net sales after commercialization.
Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

Instead of having a pipeline with numerous indications and multiple therapies, it’s this single treatments and a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.
The opening banner of its on the website of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple presentations and multiple publications.
Can all this be smoke and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this particular organization. Judging by the multiples of thousands of various comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this particular question.
CytoDyn is a traditional battleground, or possibly some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News